Cancer NetworkOriginal article
<![CDATA[Switching to SC Dosing and Considering PRO Data for Amivantamab in NSCLC]]>
Phase 3positiveamivantamabchemotherapyPositive
AI Analysis
Summary
The phase 3 PAPILLON trial showed that amivantamab plus chemotherapy improved time to worsening of symptoms compared with chemotherapy alone in NSCLC patients. The article discusses switching to subcutaneous dosing and considering patient-reported outcomes data.
Clinical Trial Data
Phase
3
Primary Endpoint
Met
Outcome Details
Time to worsening of symptoms improved with amivantamab plus chemotherapy vs chemotherapy alone
Importance:7/10
Sentiment:
0.60
oncologyNSCLCsymptom improvementcombination therapy
Read the original article
Published by Cancer Network on September 25, 2026 5:00 PM